全文获取类型
收费全文 | 764701篇 |
免费 | 60542篇 |
国内免费 | 26021篇 |
专业分类
耳鼻咽喉 | 7336篇 |
儿科学 | 18337篇 |
妇产科学 | 10345篇 |
基础医学 | 102319篇 |
口腔科学 | 14675篇 |
临床医学 | 72004篇 |
内科学 | 130387篇 |
皮肤病学 | 10700篇 |
神经病学 | 47520篇 |
特种医学 | 24182篇 |
外国民族医学 | 150篇 |
外科学 | 75164篇 |
综合类 | 99670篇 |
现状与发展 | 82篇 |
一般理论 | 33篇 |
预防医学 | 48833篇 |
眼科学 | 12862篇 |
药学 | 89555篇 |
223篇 | |
中国医学 | 29251篇 |
肿瘤学 | 57636篇 |
出版年
2024年 | 1259篇 |
2023年 | 10198篇 |
2022年 | 17252篇 |
2021年 | 33179篇 |
2020年 | 25535篇 |
2019年 | 28925篇 |
2018年 | 25029篇 |
2017年 | 24108篇 |
2016年 | 25670篇 |
2015年 | 29667篇 |
2014年 | 48381篇 |
2013年 | 50939篇 |
2012年 | 47988篇 |
2011年 | 50360篇 |
2010年 | 43560篇 |
2009年 | 42999篇 |
2008年 | 40913篇 |
2007年 | 40232篇 |
2006年 | 35639篇 |
2005年 | 29481篇 |
2004年 | 23014篇 |
2003年 | 20267篇 |
2002年 | 15989篇 |
2001年 | 14311篇 |
2000年 | 12000篇 |
1999年 | 10614篇 |
1998年 | 9041篇 |
1997年 | 8335篇 |
1996年 | 7697篇 |
1995年 | 7162篇 |
1994年 | 6459篇 |
1993年 | 5458篇 |
1992年 | 5105篇 |
1991年 | 4586篇 |
1990年 | 4039篇 |
1989年 | 3673篇 |
1988年 | 3413篇 |
1987年 | 2790篇 |
1986年 | 2459篇 |
1985年 | 4401篇 |
1984年 | 4641篇 |
1983年 | 3339篇 |
1982年 | 3741篇 |
1981年 | 3351篇 |
1980年 | 2811篇 |
1979年 | 2396篇 |
1978年 | 1856篇 |
1977年 | 1622篇 |
1976年 | 1554篇 |
1975年 | 1069篇 |
排序方式: 共有10000条查询结果,搜索用时 138 毫秒
21.
Wuteng Cao Huabin Hu Jiao Li Qianyu Wu Lishuo Shi Biao Li Jie Zhou Xinhua Wang Junhong Chen Chao Wang Huaiming Wang Weihao Deng Yan Huang Yanhong Deng 《International journal of cancer. Journal international du cancer》2023,153(11):1894-1903
Neoadjuvant programmed cell death protein 1 (PD-1) blockade exhibits promising efficacy in patients with mismatch repair deficient (dMMR) colorectal cancer (CRC). However, discrepancies between radiological and histological findings have been reported in the PICC phase II trial (NCT 03926338). Therefore, we strived to discern radiological features associated with pathological complete response (pCR) based on computed tomography (CT) images. Data were obtained from the PICC trial that included 36 tumors from 34 locally advanced dMMR CRC patients, who received neoadjuvant PD-1 blockade for 3 months. Among the 36 tumors, 28 (77.8%) tumors achieved pCR. There were no statistically significant differences in tumor longitudinal diameter, the percentage change in tumor longitudinal diameter from baseline, primary tumor sidedness, clinical stage, extramural venous invasion status, intratumoral calcification, peritumoral fat infiltration, intestinal fistula and tumor necrosis between the pCR and non-pCR tumors. Otherwise, tumors with pCR had smaller posttreatment tumor maximum thickness (median: 10 mm vs 13 mm, P = .004) and higher percentage decrease in tumor maximum thickness from baseline (52.9% vs 21.6%, P = .005) compared to non-pCR tumors. Additionally, a higher proportion of the absence of vascular sign (P = .003, odds ratio [OR] = 25.870 [95% CI, 1.357-493.110]), nodular sign (P < .001, OR = 189.000 [95% CI, 10.464-3413.803]) and extramural enhancement sign (P = .003, OR = 21.667 [2.848-164.830]) was observed in tumors with pCR. In conclusion, these CT-defined radiological features may have the potential to serve as valuable tools for clinicians in identifying patients who have achieved pCR after neoadjuvant PD-1 blockade, particularly in individuals who are willing to adopt a watch-and-wait strategy. 相似文献
22.
目的:探讨脑出血对酵母沉默信息调节因子2(Sirt2)和炎症的影响。方法:将胶原酶Ⅳ注入SD大鼠右侧
纹状体中建立脑出血模型,通过免疫印迹和ELISA 等方法测定大鼠脑出血后48 h 的Sirt2 的表达及炎症变化。利
用Hemin 诱导PC12 细胞损伤模拟体外脑出血模型,并检测Sirt2 及炎症变化;采用短发夹RNA(shRNA)-Sirt2 沉
默Sirt2 在PC12 细胞中的表达及对炎症的影响。结果:手术后48 h 脑出血行为学评分最低。脑出血组Sirt2 的表达
显著高于假手术组。脑出血组IL-6、IL-1β 表达显著升高。结论:脑出血可以促进Sirt2 的表达和炎症反应,降低
Sirt2 的表达可减缓炎症反应。
关键词 脑出血;沉默信息调节 相似文献
23.
24.
25.
26.
27.
《Revista de gastroenterologia de Mexico》2022,87(1):52-58
IntroductionThe sofosbuvir-velpatasvir (SOF/VEL) combination is a direct-acting antiviral therapy that is authorized and available in Mexico, making the performance of a real-world multicenter study that evaluates the sustained virologic response at 12 weeks post-treatment a relevant undertaking.MethodsA retrospective review of the case records of 241 patients seen at 20 hospitals in Mexico was conducted to assess hepatitis C treatment with the SOF/VEL combination (n = 231) and the sofosbuvir/velpatasvir/ribavirin (SOF/VEL/RBV) combination (n = 10). The primary efficacy endpoint was the percentage of patients that achieved SVR at 12 weeks after the end of treatment.ResultsOverall SVR was 98.8% (95% CI 97.35-100%). Only three patients did not achieve SVR, two of whom had cirrhosis and a history of previous treatment with peg-IFN. Of the subgroups analyzed, all the patients with HIV coinfection, three patients with genotype 3, and the patients treated with the SOF/VEL/RBV combination achieved SVR. The subgroups with the lower success rates were patients that were treatment-experienced (96.8%) and patients with F1 fibrosis (95.5%). The most frequent adverse events were fatigue, headache, and insomnia. No serious adverse events were reported.ConclusionTreatments with SOF/VEL and SOF/VEL/RBV were highly safe and effective, results coinciding with those of other international real-world studies. 相似文献
28.
We present the case of a male patient with severe SARS-CoV-2 pneumonia, with simultaneous onset of p-ANCA positive rapidly progressive glomerulonephritis. We discuss the different therapeutic possibilities, emphasising the appropriateness of their administration according to the time in the course of the infection. 相似文献
29.
30.